American Journal of Infectious Diseases and Microbiology
ISSN (Print): 2328-4056 ISSN (Online): 2328-4064 Website: http://www.sciepub.com/journal/ajidm Editor-in-chief: Maysaa El Sayed Zaki
Open Access
Journal Browser
Go
American Journal of Infectious Diseases and Microbiology. 2020, 8(3), 88-94
DOI: 10.12691/ajidm-8-3-1
Open AccessReview Article

Leprosy: A Review of History, Clinical Presentation and Treatments

Kashini Andrew1, and Mivanyi Kadala2

1Stroke Medicine, Morriston Hospital, Swansea, Wales

2General Medicine, Northern General Hospital, Sheffield, England

Pub. Date: August 24, 2020

Cite this paper:
Kashini Andrew and Mivanyi Kadala. Leprosy: A Review of History, Clinical Presentation and Treatments. American Journal of Infectious Diseases and Microbiology. 2020; 8(3):88-94. doi: 10.12691/ajidm-8-3-1

Abstract

Leprosy is an ancient disease of mankind that has persisted for generations across various continents. The disease is caused by Mycobacterium leprae and Mycobacterium lepromatosis with humans acting as the natural reservoir. The transmission of Leprosy is still poorly understood, however it is widely accepted that the inhalation of aerosol droplets from cases with high mycobacterial loads is the most common mechanism. Leprosy affects the skin and peripheral nerves and has been a focus of a worldwide eradication campaign by the World Health Organisation which has been largely successful. Treatment is with the use of a multi drug therapy with Dapsone, Rifampicin and Clofazamin for 6 to 12 months depending on the type of leprosy.

Keywords:
leprosy Mycobacterium leprae Mycobacterium lepromatosis

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Skinsnes O. Notes from the History of leprosy. International journal of leprosy. 1973; 41(2): 1.
 
[2]  Browne S. Some Aspects of the History of Leprosy: The Leprosie of Yesterday [Internet]. Journals.sagepub.com. 1975 [cited 25 May 2020]. Available from: https://journals.sagepub.com/doi/pdf/10.1177/00359157750680080.
 
[3]  Bennett BH, Parker DL. and Robson M. Leprosy: steps along the journey of eradication. Public Health Reports, 2008, 123(2), 198-205.
 
[4]  Monot M, Honoré N, Garnier T, Araoz R, Coppée JY, Lacroix C, et al. On the origin of leprosy. Science; 2005, 308(5724): 1040-1042.
 
[5]  Robbins G, Tripathy VM, Misra VN, Mohanty RK, Shinde VSG, Kelsey M. et al. "Ancient Skeletal Evidence for Leprosy in India (2000 B.C.)" PLOS ONE. 2000, 4(5): e5669.
 
[6]  Trautman JR. A brief history of Hansen's disease. Bulletin of the New York Academy of Medicine. 1984;60(7):689-695.
 
[7]  Venita J. The legacy of Armauer Hansen. A portrait in history. Archives of Pathology and Laboratory Medicine 2000; (4)124: 496-497.
 
[8]  World Health Organisation. Leprosy fact sheet. 2000 Available from: https://www.who.int/news-room/fact-sheets/detail/leprosy (accessed 25/5/2020).
 
[9]  Rao P N. Global leprosy strategy 2016-2020: Issues and concerns. Indian Journal of Dermatology, Venereology and Leprology [serial online (cited 2020 May 17) 2017; 83: 4-6.
 
[10]  Victor SS, Carlos DFS, Paulo RS, Martin F and Luis E. Cuevas Leprosy: why does it persist among us? Expert Review of Anti-infective Therapy, 2020.
 
[11]  World Health Organisation, Facts Sheet on Leprosy, 2019, (Cited 2020 June 02)Available at: https://www.who.int/en/news-room/fact-sheets/detail/leprosy.
 
[12]  World Health Organisation, Neglected Tropical Diseases: News, 2019 ,(Cited 2020 June 02) Available at: https://www.who.int/neglected_diseases/news/Leprosy-new-data- show-steady-decline-in-new-cases/en/.
 
[13]  Ploemacher T, Faber WR, Menke H, Rutten V, Pieters T. Reservoirs and transmission routes of leprosy; A systematic review. PLoS Neglected Tropical Diseases. 2020; 14(4): e0008276. Published 2020 Apr 27.
 
[14]  World Health Organisation, Global Health Data Repository: Leprosy- Number of new leprosy cases Data per country (Cited 2020 May 24th).
 
[15]  Oliveira IVP, Deps PD, Antunes JMAP. Armadillos and leprosy: from infection to biological model. Revista do Instituto de Medicina Tropical de Sao Paulo. 2019; 61: e44. Published 2019 Sep 12.
 
[16]  Ramesh MB and Chaitra P. Leprosy: An Overview of Pathophysiology, Interdisciplinary Perspectives on Infectious Disease 2012: 181089. Published online 2012 sep 4.
 
[17]  Marcellus F. Leprosy - an overview of clinical features, diagnosis, and treatment, Journal of the German society of dermatology August 2017 vol 15(08), 801-827.
 
[18]  Job CK, Jayakumar J, Kearney M, Gillis TP. Transmission of leprosy: A study of skin and nasal secretions of household contacts of leprosy patients using PCR. The American Journal of Tropical Medicine and Hygiene. 2008; 78(3): 518-521.
 
[19]  Satapathy J, Kar BR, Job CK. Presence of Mycobacterium leprae in epidermal cells of lepromatous skin and its significance. Indian Journal of Dermatology, Venereology and Leprology. 2005; 71(4): 267-269.
 
[20]  Bruce S, Schroeder TL, Ellner K, Rubin H, Williams T, Wolf JE. Armadillo exposure and Hansen’s disease: An epidemiologic survey in southern Texas. Journal of the American Academy of Dermatology. 2000; 43(2): 223-228S.
 
[21]  Rambukkana, A, Zanazzi G, Tapinos, N., and Salzer, J L “Contact-dependent demyelination by Mycobacterium leprae in the absence of immune cells,” Science, 2002, 296(5569), pp. 927-931.
 
[22]  Marques MAM, Antônio VL, Sarno EN, Brennan PJ, and Pessolani MCV, “Binding of α2-laminins by pathogenic and non-pathogenic mycobacteria and adherence to Schwann cells,” Journal of Medical Microbiology, 2001, 50(1), pp. 23-28.
 
[23]  Tapinos N, Ohnishi M, and Rambukkana A, “ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli,” Nature Medicine, 2006, 12(8), pp. 961-966.
 
[24]  Rambukkana A, Yamada H, Zanazzi G, Mathus T, Salzer JL Yurchenco PD et al., “Role of α-dystroglycan as a Schwann cell receptor for Mycobacterium leprae,” Science, 1998, 282(5396), pp. 2076-2079.
 
[25]  Ridley DS. and Jopling WH. “Classification of leprosy according to immunity. A five-group system,” International Journal of Leprosy and Other Mycobacterial Diseases,1966, 34(3), pp. 255-273.
 
[26]  Fajardo TT, “Indeterminate leprosy: a five year study, clinical observations,” International Journal of Leprosy, 1973, Vol 41, p. 576.
 
[27]  Canizares O, Harman R, Adriaans B. Leprosy. In: Canizares O, Harman R, editors. Clinical Tropical Dermatology. 2nd ed. Boston: Blackwell Scientific; 1992. pp. 165-200.
 
[28]  Elinav H, Palladas L, Applbaum YH, Gilead L, Moses AE, Cohen-Poradosu R. Plantar ulcers and eyebrow-hair paucity. Clinical Infectious Diseases. 2006; 42(5): 684-685, 722-724.
 
[29]  Akpolat ND, Akkus A and Kaynak E. An Update on the Epidemiology, Diagnosis and Treatment of Leprosy, (Cited 2020 July 3rd): 2018.
 
[30]  Sehgal VN and Srivastava G, “Status of histoid leprosy-a clinical, bacteriological, histopathological and immunological appraisal,” Journal of Dermatology, 1987, 14(1), pp. 38-42, 1987.
 
[31]  Sehgal VN, Tuli MS, and Dube B, “Leprotic nerve abscesses in northern India,” International Journal of Leprosy and Other Mycobacterial Diseases, 1967, 35(1), pp. 60-64.
 
[32]  Britton W. Leprosy. In: Cohen J, Powderly WG, editors. Infectious Diseases. London: Mosby; 2003. pp. 1507-1513.
 
[33]  Walker SL. 2020 Leprosy reactions. In Gillis TP (ed), International textbook of leprosy. Accessed 13/6/2020.
 
[34]  Scollard DM et al. 1993. Epidemiological characteristics of leprosy. International journal of leprosy. Volume 62, No 4. Available from http://ila.ilsl.br/pdfs/v62n4a09.pdf. Accessed 13/6/2020.
 
[35]  Scollard DM et al. The continuing challenges of leprosy. Clinical microbiology reviews. 2006; 19(2): 338-381.
 
[36]  Scollard D et al. 2020 Leprosy; epidemiology, microbiology, clinical manifestations and diagnosis. In Baron, E (ed). Uptodate. Accessed 13/6/2020 https://www.uptodate.com/contents/leprosy- epidemiology-microbiology-clinical-manifestations-and- diagnosis?search=diagnosis%20of%20leprosy&source=search_res ult&selectedTitle=1~95&usage_type=default&display_rank=1#H15.
 
[37]  World health organisation. Guidelines for the diagnosis, treatment and prevention of leprosy. Available from https://apps.who.int/iris/bitstream/handle/10665/274127/97892902 26383-eng.pdf?sequence=10&isAllowed=y. Accessed 13/6/2020.
 
[38]  National Hansen disease programme. NHDP guide to the management of Hansen disease. Available from https://www.hrsa.gov/sites/default/files/hrsa/hansens- disease/pdfs/hd-guide-management.pdf. Accessed 13/6/2020.
 
[39]  WHO Study Group on Chemotherapy of Leprosy for Control Programmes & World Health Organization. (‎1982)‎. Chemotherapy of leprosy for control programmes: report of a WHO study group World Health Organization. https://apps.who.int/iris/handle/10665/38984. Accessed 12/6/2020.
 
[40]  WHO Expert Committee on Leprosy. WHO Expert Committee on Leprosy: seventh report. WHO Technical Report Series No. 874. Geneva: WHO; 1998. http://www.who.int/iris/handle/10665/42060, Accessed 20th June 2020.
 
[41]  Guidelines for the diagnosis, treatment and prevention of leprosy. New Delhi: World Health Organization, Regional Office for South-East Asia; https://apps.who.int/iris/bitstream/handle/10665/274127/97892902 26383-eng.pdf?ua=1 Accessed 20th June 2020.